MiNK Therapeutics announces publication of case report on agenT-797

MiNK Therapeutics announced the publication of a case report in Oncogene from its phase 1/2 study in patients with advanced solid tumors where one infusion of agenT-797 in gastric cancer refractory to anti-PD1 led to a durable confirmed partial response, highlighting the unique potential of iNKT cells to overcome resistance to immune checkpoint inhibitors, ICIs. “Gastric cancer remains an area of high unmet need, where the majority of patients develop disease progression related to tumor resistance,” said Dr. Benedito Carneiro, Director of Clinical Research, Director of Cancer Drug Development, Associate Director of the Division of Hematology/Oncology, Legorreta Cancer Center at Brown University. “Novel therapeutic approaches, like allogeneic iNKT cells, are urgently needed to overcome resistance to immune checkpoint inhibitors in gastric cancers and other refractory solid tumors. The activity, tolerability, and ease of off-the-shelf administration of iNKT-based cell therapies position them as an attractive approach for overcoming cancer resistance.” This case report describes a durable response in a patient with a challenging clinical profile-a PD-L1 positive, HER-2 negative, MSI-H adenocarcinoma with a high mutational burden. Prior treatments, including single-agent anti-PD-1 pembrolizumab, had failed to elicit a response, prompting a combination therapy approach involving chemotherapy and nivolumab. However, even this combined regimen proved ineffective before the patient’s enrollment in MiNK’s clinical trial. Following treatment with agenT-797, increased immune cell infiltration and proliferation were observed, which correlated with the radiographic partial response.